: Corteria Pharmaceuticals: Pioneering Heart Failure Solutions Corteria Pharmaceuticals, a trailblazer in the biopharmaceutical sector, has recently announced the commencement of its Phase 1 study for COR-1167, a novel corticotropin-releasing hormone receptor 2 (CRF2) agonist. This study marks a significant stride in the quest to address the unmet medical needs of patients suffering from Worsening Heart Failure (WHF). The COR-1167 Potential Unveiling a First-in-Class Therapy COR-1167 is not just another drug; it’s a potential game-changer in heart failure treatment. Administered once daily through subcutaneous injection, it has already demonstrated impressive protective and functional improvements in heart, vascular, and renal functions in The post A New Dawn in Heart Failure Treatment: Breakthrough Study Launched appeared first on Business Today